Category Business

Royalty Pharma and Revolution Medicines Sign Funding Deals Worth Up to $2 Billion

Royalty Pharma and Revolution Medicines Forge $2 Billion Strategic Funding Pact to Accelerate Global Development of RAS Cancer Therapies Royalty Pharma plc, a prominent funder of innovation in the biopharmaceutical industry, announced a transformative agreement with Revolution Medicines, Inc., securing…

Read MoreRoyalty Pharma and Revolution Medicines Sign Funding Deals Worth Up to $2 Billion

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership. Extending their 16-year collaboration…

Read MoreBayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

AbbVie and ADARx Pharmaceuticals Forge Collaboration and Licensing Deal to Advance Next-Gen siRNA Therapies Across Diverse Disease Areas

AbbVie and ADARx Partner to Advance Next-Generation siRNA Therapies Across Neuroscience, Immunology, and Oncology in Multibillion-Dollar Collaboration AbbVie, a global biopharmaceutical leader known for its portfolio of therapies in immunology, oncology, neuroscience, and other specialty areas, has announced a significant…

Read MoreAbbVie and ADARx Pharmaceuticals Forge Collaboration and Licensing Deal to Advance Next-Gen siRNA Therapies Across Diverse Disease Areas
Innate

Innate Pharma Announces First Quarter 2025 Financial Results and Business Highlights

Innate Pharma Announces First Quarter 2025 Financial Results and Business Highlights Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage oncology-focused biotechnology company pioneering innovative immunotherapies, announced its consolidated financial results for the first quarter ending March 31, 2025,…

Read MoreInnate Pharma Announces First Quarter 2025 Financial Results and Business Highlights

Sanofi Highlights Scientific Leadership and Innovation in Chronic Inflammatory Respiratory Diseases at ATS

Sanofi Showcases Expansive Respiratory Innovation and Scientific Leadership at ATS 2025 with Robust Clinical Data from Dupixent and Immunology Pipeline Sanofi is poised to make a major impact at the 2025 American Thoracic Society (ATS) International Conference, taking place from…

Read MoreSanofi Highlights Scientific Leadership and Innovation in Chronic Inflammatory Respiratory Diseases at ATS